Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®)[Teijin]

- 1 - February 26, 2021 To whom it may concern Company: Teijin Limited Representative: Jun Suzuki, President and CEO Stock code: 3401 (First Section, Tokyo Stock Exchange) Contact: Tomoko Torii, General Manager Investor Relations Department TEL: +81-3-3506-4395 Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®) Teijin Limited (“Teijin”) announces that it has decided that Teijin and its subsidiary Teijin Pharma Limited (Head Office: Chiyoda-ku, Tokyo; President and Representative Director: Ichiro Watanabe; hereinafter "Teijin Pharma") has entered into an asset transfer agreement (“Asset Transfer Agreement”) with Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President & CEO: Christophe Weber; hereinafter "Takeda") to transfer the Japan sales of type 2 diabetes treatments manufactured and sold by Takeda in Japan, namely Nesina® tablets 6.25 mg, 12.5 mg, 25 mg(Generic name: alogliptin benzoate), Liovel® combination tablets H D, Liovel® combination tablets LD (Generic name: alogliptin benzoate/ pioglitazone hydrochloride ), Inisync® combination tablets (Generic name: alogliptin benzoate/metformin hydrochloride ), and Zafatek® tablets 25 mg, 50 mg, 100 mg (Generic name: trelagliptin succinate) (collectively the "Products"), to Teijin Pharma and to transfer relevant intellectual properties (including patents) and manufacturing and marketing approvals to Teijin Pharma. As of April 1, 2021, p rior to the transfer of the manufacturing and marketing approvals, the sale of the Products will be transferred to Teijin Pharma after the procedures stipulated in the Asset Transfer Agreement are completed, and thereafter Teijin Pharma will be selling the Products and providing and collecting relevant information. Once all necessary procedures with the Ministry of Health, Labour and Welfare are completed, Teijin Pharma will take over the manufacturing and marketing approvals. 1. Reasons for Transfer of Sales and Manufacturing and Marketing Approvals Based on its corporate philosophy of " Enhancing the Quality of Life ," Teijin is working towards the realization of a sustainable society by delivering value to the society through solutions in the three fields of “Environmental Value,” “Safety, Security, and Disaster Mitigation,” and “Demographic Change and Increased Health Consciousness ,” with the aim of becoming a “ Company that Supports the Society of the Future .” On February 5, 2020, Teijin announced its Medium-Term Management Plan for 2020-2022 “ALWAYS EVOLVING" ("Medium-Term Management Plan") and positioned the period of the M edium-Term Management Plan as a period of “Creating Growth Platforms .” Under the Medium-Term Management Plan, Teijin is making aggressive investments in businesses that need to be developed to become future sources of earnings, which are classified as "Strategic Focus," as well as in businesses that are already profitable and aiming for further growth , which are classified as "Profitable Growth." Teijin Group’s healthcare business is working to provide “Demographic Change and Increased Health Consciousness Solutions” in Japan, which is one of the most aged society in the world. Teijin Group is committed to maintaining and strengthening the R&D and marketing platforms and the service network for healthcare professionals and patients established through its pharmaceuticals and home healthcare businesses, which are positioned as "Profitable Growth ." At the same time, it is aiming to become a comprehensive community-based healthcare provider in sectors including rehabilitation, nursing care, prevention and health promotion, which is positioned as "Strategic Focus," through such initiatives as deploying VitalLink, a support tool for providing a comprehensive community healthcare - 2 - system, and expanding the operation of visiting nursing stations. In the area of prevention and health promotion, Teijin Group has started the functional food business and providing services not covered by Japan’s health insurance system, such as lifestyle modification guidance service using applications and monitoring devices. Teijin Group is also working on accelerating the creation of innovative medical treatment and creating new businesses by integrating Teijin’s healthcare, materials, and engineering technology platforms. The Products consist of dipeptidyl peptidase-4 (DPP-4) inhibitors and its combination tablets, which reduce blood glucose levels . They are orally taken drugs developed by Takeda and are used for treatment of many type 2 diabetes patients in Japan and overseas. On the other hand, Teijin Group has been working to improve the QOL of patients with lifestyle -related diseases by providing FEBURIC®, a hyperuricemia and gout treatment, and CPAP therapy device for the treatment of sleep apnea syndrome. As cardiovascular and metabolic field is one of Teijin Pharma’s focus areas, being able to take over the Products that have strong brand power will lead to maintaining and strengthening its business platform for future business expansion. Further, the addition of these type 2 diabetes treatments to Teijin Group’s key offerings and the strengthening of business platform will accelerate its efforts in disease treatment, as well as the expansion of services that contribute to the prevention of lifestyle-related diseases and the reduction in progression of such diseases, which are part of the “Strategic Focus" of Teijin Group. Based on the above, Teijin Group has decided to take over t he manufacturing and marketing approvals of the Products in Japan to aim for further growth of its healthcare business by creating synergies and strengthening the business platform with expanded product portfolio by acquiring the Products. To ensure stable delivery of the Products to patients, Teijin Group will work closely with Takeda for a smooth and efficient transfer of the sales and manufacturing and marketing approvals of the Products. 2. Overview of Transfer of Sales of Products and Manufacturing and Marketing Approvals (1) Products Brand name Therapeutic category Nesina® tablets 6.25 mg Nesina® tablets 12.5 mg Nesina® tablets 25 mg Selective DPP-4 inhibitor Drugs for treating type 2 diabetes Liovel® combination tablets HD Liovel® combination tablets LD Fixed dose combination tablets of selective DPP -4 inhibitor and thiazolidinediones Drugs for treating type 2 diabetes Inisync® combination tablets Fixed dose combination tablets of selective DPP -4 inhibitor and biguanides Drugs for treating type 2 diabetes Zafatek® tablets 25 mg Zafatek® tablets 50 mg Zafatek® tablets 100 mg Long-acting selective DPP-4 inhibitor Drugs for treating type 2 diabetes (2) Operating results of Products Total sales of the Products in Japan for the fiscal year ended March 2020 were approximately 30.8 billion yen. (3) Items of assets concerning Products Items of assets will include inventory assets concerning the Products and intangible fixed assets such as transfer of Japan sales, intellectual properties (including patents), and manufacturing and marketing approvals. - 3 - (4) Transfer price of Products The transfer price of the Products is expected to be 133 billion yen, including inventory assets, which will be adjusted to reflect the amount of inventory assets at the time of transfer. 3. Outline of Transferee of Sales of Products and Manufacturing and Marketing Approvals (1) Name Teijin Pharma Limited (2) Location Kasumigaseki Common Gate West Tower 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo (3) Name and title of representative Ichiro Watanabe, President (4) Business description Sales, marketing, manufacturing and research and development of pharmaceuticals and medical devices (5) Paid-in capital 10 billion yen (6) Date of incorporation April 15, 2002 (7) Major shareholder and shareholding ratio Teijin Limited 100% (8) Relationship between Teijin and Teijin Pharma Capital relationship Teijin owns 100% of shares in Teijin Pharma. Personnel relationship Three employees of Teijin concurrently serve as President, Director, and Statutory Auditor of Teijin Pharma and there are other employees of Teijin who are seconded to Teijin Pharma. Transactional relationship Teijin has business transactions with Teijin Pharma, including intellectual property agreements and loans. Status as a related party Teijin Pharma is a consolidated subsidiary of Teijin. (9) Operating and financial results for the past three years (standalone basis) Fiscal year ended March 31, 2018 March 31, 2019 March 31, 2020 Net assets 42,991 million yen 50,255 million yen 52,507 million yen Total assets 112,117 million yen 111,734 million yen 102,364 million yen Net sales 125,410 million yen 124,196 million yen 119,366 million yen Operating income 13,037 million yen 14,324 million yen 16,511 million yen Ordinary income 13,559 million yen 14,600 million yen 17,135 million yen Net income 10,268 million yen 14,199 million yen 12,477 million yen 4. Outline of Transferor (1) Name Takeda Pharmaceutical Company Limited (2) Location 1-1, Doshomachi 4-chome, Chuo-ku, Osaka (3) Name and title of representative Christophe Weber, President & CEO (4) Business description Research and development, manufacturing, sales and marketing, and import/export of pharmaceutical drugs, etc. (5) Paid-in capital (as of Sep. 30, 2020) 1,668.1 billion yen (6) Date of incorporation January 12, 1925 The Master Trust Bank of Japan, Ltd. (Trust Account) 9.02% - 4 - (7) Major shareholders and shareholding ratio (as of Sep. 30, 2020) Custody Bank of Japan, Ltd. (Trust Account) 5.53% The Bank of New York Mellon as Depositary Bank for Depositary Receipt Holders (Standing Proxy: Sumitomo Mitsui Banking Corporation) 4.94% Nippon Life Insurance Company (Standing Proxy: The Master Trust Bank of Japan, Ltd.) 2.24% JP Morgan Chase Bank 385632 (Standing Proxy: Mizuho Bank, Ltd.) 2.24% Custody Bank of Japan, Ltd. (Trust Account 5) 2.20% SSBTC Client Omnibus Account (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch) 1.59% JP Morgan Chase Bank 385781 (Standing Proxy: Mizuho Bank, Ltd.) 1.54% State Street Bank West Client-Treaty 505234 (Standing Proxy: Mizuho Bank, Ltd.) 1.52% State Street Bank and Trust Company 505001 (Standing Proxy: Mizuho Bank, Ltd.) 1.30% (8) Relationship between Teijin and Takeda Capital relationship N/A Personnel relationship N/A Transactional relationship Teijin Pharma, Teijin’s consolidated subsidiary, has a contract with Takeda Pharmaceuticals U.S.A., Inc., a consolidated subsidiary of Takeda, for the US sales of ULORIC®, a treatment for gout and hyperuricemia. Teijin Pharma also had business transactions with Takeda concerning raw materials for pharmaceuticals. Status as a related party N/A (9) Operating and financial results for the past three years Fiscal year ended March 31, 2018 March 31, 2019 March 31, 2020 Total equity 2,017,409 million yen 5,185,991 million yen 4,727,486 million yen Total assets 4,106,463 million yen 13,792,773 million yen 12,821,094 million yen Revenue 1,770,531 million yen 2,097,224 million yen 3,291,188 million yen Operating profit 241,789 million yen 237,685 million yen 100,408 million yen Net profit for the year 186,708 million yen 135,080 million yen 44,290 million yen 5. Timeline Board resolution February 26, 2021 (today) Execution of Asset Transfer Agreement February 26, 2021 (today) Transfer of sales of Products April 1, 2021 (scheduled) Transfer of manufacturing and marketing approvals Scheduled after necessary procedures with t he Ministry of Health, Labour and Welfare are completed 6．Future Outlook Since the date of the transfer of sales of the Products is scheduled for the nextconsolidated fiscal year, there will be no impact on Teijin's consolidated operating results for the fiscal year ending March 31, 2021. The impact of this transaction will be reflected in the operating results of the next fiscal year.

The release as fetched from its publisher. teijin.com ↗